BR112015022617A2 - polipeptídeo recombinante termoestável, composição imunogênica, vetor de expressão recombinante e uso de um polipeptídeo recombinante termoestável - Google Patents
polipeptídeo recombinante termoestável, composição imunogênica, vetor de expressão recombinante e uso de um polipeptídeo recombinante termoestávelInfo
- Publication number
- BR112015022617A2 BR112015022617A2 BR112015022617A BR112015022617A BR112015022617A2 BR 112015022617 A2 BR112015022617 A2 BR 112015022617A2 BR 112015022617 A BR112015022617 A BR 112015022617A BR 112015022617 A BR112015022617 A BR 112015022617A BR 112015022617 A2 BR112015022617 A2 BR 112015022617A2
- Authority
- BR
- Brazil
- Prior art keywords
- thermostable
- recombinant polypeptide
- expression vector
- immunogenic composition
- polypeptide
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 230000002163 immunogen Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000013604 expression vector Substances 0.000 title abstract 2
- 238000003259 recombinant expression Methods 0.000 title abstract 2
- 230000000890 antigenic effect Effects 0.000 abstract 2
- 230000008105 immune reaction Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004961 Furin Human genes 0.000 abstract 1
- 108090001126 Furin Proteins 0.000 abstract 1
- 241000725643 Respiratory syncytial virus Species 0.000 abstract 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 abstract 1
- 230000001086 cytosolic effect Effects 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000005829 trimerization reaction Methods 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/828,667 US9060975B2 (en) | 2013-03-14 | 2013-03-14 | Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions |
| PCT/EP2014/054804 WO2014140083A1 (en) | 2013-03-14 | 2014-03-12 | Heat-stable respiratory syncytial virus prefusion f protein oligomers and their use in immunological compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015022617A2 true BR112015022617A2 (pt) | 2017-10-31 |
Family
ID=50241453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015022617A BR112015022617A2 (pt) | 2013-03-14 | 2014-03-12 | polipeptídeo recombinante termoestável, composição imunogênica, vetor de expressão recombinante e uso de um polipeptídeo recombinante termoestável |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9060975B2 (https=) |
| EP (2) | EP3178840A1 (https=) |
| JP (1) | JP6285469B2 (https=) |
| CN (2) | CN107029227A (https=) |
| AU (1) | AU2014230822B2 (https=) |
| BR (1) | BR112015022617A2 (https=) |
| CA (1) | CA2905571A1 (https=) |
| WO (1) | WO2014140083A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2900110A1 (en) | 2013-02-01 | 2014-08-07 | Medimmune, Llc | Respiratory syncytial virus f protein epitopes |
| EP3798310A1 (en) | 2013-03-14 | 2021-03-31 | Emory University | Recombinant rsv with silent mutations, vaccines, and methods related thereto |
| MX2018005462A (es) | 2015-10-29 | 2018-08-01 | Univ Emory | Composiciones inmunogénicas de rsv quimérico y métodos de uso. |
| IL262108B2 (en) * | 2016-04-05 | 2023-04-01 | Janssen Vaccines Prevention B V | Soluble pre-fusion rsv f proteins are stabilized |
| CN109311946A (zh) * | 2016-05-30 | 2019-02-05 | 扬森疫苗与预防公司 | 稳定化的融合前rsv f蛋白 |
| CN108300705B (zh) * | 2017-01-12 | 2021-10-22 | 厦门大学 | 稳定呼吸道合胞病毒融合蛋白的方法 |
| KR20260047644A (ko) | 2017-03-30 | 2026-04-08 | 더 유니버서티 어브 퀸슬랜드 | 키메라 분자 및 그의 용도 |
| HUE073526T2 (hu) | 2017-04-04 | 2026-01-28 | Univ Washington | Önmagát összeállító fehérje nanostruktúrák, amelyek paramyxovírus és/vagy pneumovírus F fehérjéket jelenítenek meg és azok használata |
| WO2019063844A1 (en) * | 2017-09-29 | 2019-04-04 | Universiteit Antwerpen | VACCINATION AGAINST SYNCYTIAL RESPIRATORY VIRUS |
| BR112020015308A8 (pt) * | 2018-01-29 | 2023-02-07 | Merck Sharp & Dohme | Proteínas f de rsv estabilizadas e usos das mesmas |
| CN110684747B (zh) * | 2018-07-06 | 2024-05-24 | 厦门大学 | 灭活及保存呼吸道合胞病毒的方法 |
| KR102725189B1 (ko) * | 2018-11-01 | 2024-10-31 | 에스케이바이오사이언스(주) | 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물 |
| CN109694400A (zh) * | 2019-01-31 | 2019-04-30 | 苏州高泓利康生物科技有限公司 | 一种表达呼吸道合胞病毒f蛋白及其制备方法 |
| CN114957407A (zh) * | 2019-04-02 | 2022-08-30 | 赛诺菲 | 抗原性多聚呼吸道合胞病毒多肽 |
| CN110054668B (zh) * | 2019-04-25 | 2021-09-10 | 北京交通大学 | 一种呼吸道合胞病毒融合前f蛋白及其应用 |
| EP4025587A1 (en) | 2019-09-04 | 2022-07-13 | University of Washington | Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use |
| CN111303245B (zh) * | 2020-02-21 | 2023-06-27 | 成都奥达生物科技有限公司 | 一种抗合胞病毒膜融合抑制剂 |
| JP7627447B2 (ja) * | 2020-04-22 | 2025-02-06 | ポステック・リサーチ・アンド・ビジネス・ディヴェロップメント・ファウンデイション | 三量体を形成するインフルエンザウイルス表面タンパク質由来組換え赤血球凝集素タンパク質およびその用途 |
| WO2021234579A1 (en) * | 2020-05-19 | 2021-11-25 | National Research Council Of Canada | Use of resistin as a trimerization partner for expression of trimeric proteins |
| CN112480217B (zh) * | 2020-11-30 | 2022-04-08 | 广州阿格纳生物医药制造有限公司 | 基于SARS-CoV-2的S抗原蛋白的疫苗和组合物 |
| KR20250140099A (ko) * | 2023-02-03 | 2025-09-24 | 노바백스, 인코포레이티드 | Rsv f 백신 제형 |
| WO2024192698A1 (zh) * | 2023-03-22 | 2024-09-26 | 中科牧维(南京)生物科技有限公司 | 靶向人呼吸道合胞病毒融合糖蛋白的多肽拮抗剂 |
| CN121464149A (zh) * | 2023-06-07 | 2026-02-03 | 四川三叶草生物制药有限公司 | Rsv疫苗组合物、方法及其用途 |
| US12383614B2 (en) | 2023-12-21 | 2025-08-12 | Yikang Biotech (Suzhou) Co., Ltd. | Mutants of respiratory syncytial virus fusion proteins |
| CN117886902B (zh) * | 2023-12-21 | 2024-11-26 | 易康生物(苏州)有限公司 | 改良的呼吸道合胞病毒融合f蛋白突变体及其应用 |
| CN121221752A (zh) * | 2025-02-14 | 2025-12-30 | 北京悦康科创医药科技股份有限公司 | 一种膜融合抑制多肽在抗副黏病毒科病毒感染中的应用 |
| CN120329390A (zh) * | 2025-03-03 | 2025-07-18 | 中国医学科学院医学生物学研究所 | 基于异源三聚体基序的蛋白的改造及应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0916726A1 (en) | 1997-11-13 | 1999-05-19 | Rijksuniversiteit te Groningen | Attaching substances to micro-organisms |
| DK1395648T3 (da) | 2001-06-11 | 2009-08-03 | Applied Nanosystems Bv | Fremgangsmåder til binding af AcmA-type proteinankerfusioner til cellevægsmateriale af mikroorganismer |
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| EP2445527A2 (en) | 2009-06-24 | 2012-05-02 | ID Biomedical Corporation of Quebec | Vaccine |
| HUE028085T2 (en) | 2009-06-24 | 2016-11-28 | Glaxosmithkline Biologicals Sa | Recombinant RSV antigens |
| CA2768186A1 (en) * | 2009-07-15 | 2011-01-20 | Novartis Ag | Rsv f protein compositions and methods for making same |
| US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
| US9585953B2 (en) | 2011-03-22 | 2017-03-07 | Mucosis B.V. | Immunogenic compositions in particulate form and methods for producing the same |
| CA2835644C (en) | 2011-05-13 | 2021-06-15 | Novartis Ag | Pre-fusion rsv f antigens |
-
2013
- 2013-03-14 US US13/828,667 patent/US9060975B2/en not_active Ceased
-
2014
- 2014-03-12 BR BR112015022617A patent/BR112015022617A2/pt not_active IP Right Cessation
- 2014-03-12 CN CN201710040168.9A patent/CN107029227A/zh active Pending
- 2014-03-12 WO PCT/EP2014/054804 patent/WO2014140083A1/en not_active Ceased
- 2014-03-12 CA CA2905571A patent/CA2905571A1/en not_active Abandoned
- 2014-03-12 JP JP2015562115A patent/JP6285469B2/ja not_active Expired - Fee Related
- 2014-03-12 CN CN201480022815.8A patent/CN105246910A/zh active Pending
- 2014-03-12 EP EP16200916.1A patent/EP3178840A1/en not_active Withdrawn
- 2014-03-12 EP EP14709318.1A patent/EP2970393B1/en not_active Not-in-force
- 2014-03-12 AU AU2014230822A patent/AU2014230822B2/en not_active Ceased
-
2016
- 2016-03-26 US US15/081,854 patent/USRE47471E1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN107029227A (zh) | 2017-08-11 |
| EP3178840A1 (en) | 2017-06-14 |
| CN105246910A (zh) | 2016-01-13 |
| AU2014230822A1 (en) | 2015-10-01 |
| US9060975B2 (en) | 2015-06-23 |
| USRE47471E1 (en) | 2019-07-02 |
| CA2905571A1 (en) | 2014-09-18 |
| AU2014230822B2 (en) | 2018-04-12 |
| JP6285469B2 (ja) | 2018-02-28 |
| EP2970393A1 (en) | 2016-01-20 |
| US20140271696A1 (en) | 2014-09-18 |
| WO2014140083A1 (en) | 2014-09-18 |
| JP2016510983A (ja) | 2016-04-14 |
| EP2970393B1 (en) | 2017-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015022617A2 (pt) | polipeptídeo recombinante termoestável, composição imunogênica, vetor de expressão recombinante e uso de um polipeptídeo recombinante termoestável | |
| EA201891415A1 (ru) | Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения | |
| CL2021001750A1 (es) | Receptores quiméricos y metodos de uso de los mismos (divisional solicitud 2677-2020) | |
| BR112018075032A2 (pt) | proteínas de hemaglutinina do vírus influenza e seus uso | |
| CO2018011804A2 (es) | Receptores quiméricos de flt3 y métodos de uso de los mismos | |
| AU2019349036A8 (en) | Immune composition, preparation method therefor, and application thereof | |
| MX2015008847A (es) | Composiciones inmunogenicas de virus de influenza y usos de las mismas. | |
| TR201903074T4 (tr) | Prostat ile bağlantılı antijenlerin ekspresyonuna yönelik vektörler. | |
| MX2015013065A (es) | Proteinas f de rsv de prefusion y su uso. | |
| BR112016028816A2 (pt) | combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório, e, kit. | |
| MX2018003298A (es) | Metodo para preparar una formulacion de proteinas terapeuticas y formulacion de anticuerpos producida por tal metodo. | |
| EA201892735A1 (ru) | Состав вакцины против hiv | |
| WO2014150822A3 (en) | Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use | |
| EA202191622A1 (ru) | Стабилизированные растворимые f-белки rsv до слияния | |
| MX389111B (es) | Vectores virales recombinantes que contienen la proteina menor del virus del sindrome reproductor y respiratorio porcino (prrsv) y sus metodos de elaboracion y uso. | |
| EA202092521A1 (ru) | Способы и композиции для индукции защитного иммунитета против инфекции вирусом иммунодефицита человека | |
| EA201691611A1 (ru) | Конструкции белка uspa2 и их применения | |
| NZ603863A (en) | Concentration and lyophilization of influenza vaccine antigens | |
| MX387396B (es) | Un poliepitope quimerico de virus de dengue compuesto por fragmentos de proteinas no estructurales y su uso en una composicion inmunogenica contra infeccion de virus de dengue. | |
| MX2018016121A (es) | Preparacion de anticuerpos monoclonales marcados con 212pb. | |
| BR112013000345A2 (pt) | composições antigênicas para vírus sincicial respiratório e métodos | |
| BR112019001115A2 (pt) | proteínas de biofusão como vacinas anti-malária | |
| WO2016061504A3 (en) | Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein | |
| MX2019006105A (es) | Conjugados de vmen-antigeno y uso de los mismos. | |
| EA201790558A1 (ru) | Композиция с пониженной иммуногенностью |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2557 DE 2020-01-07 |